LGALS3 and Myocardial fibrosis: For example, spironolactone administration reduces the Gal-3 concentrations in patients with reduced ejection fractions, which shows a potential beneficial therapeutic outcome of the inhibition of the renin–angiotensin–aldosterone axis for the prevention of myocardial fibrosis and remodeling processes [25].